Immunotherapy with anti-CD20 compounds

被引：15

作者：

von Schilling, C ^{[1
]}

机构：

[1] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 3, D-81675 Munich, Germany

来源：

SEMINARS IN CANCER BIOLOGY | 2003年 / 13卷 / 03期

关键词：

B-cell lymphoma; CD20; clinical trials; monoclonal antibody;

D O I：

10.1016/S1044-579X(03)00018-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The B-cell surface antigen CD20 is currently the prime target for near-selective treatment of mature B-cell malignancies and a range of reactive B-cell associated disorders (including virus-associated lymphoproliferation or autoimmune conditions). CD20 is strongly and homogeneously expressed on the majority of mature B-cell neoplasms except chronic lymphocytic leukaemia cells, and on all mature reactive B-cells. This review will summarise the modes of action of various reagents targeting CD20. Treatment results following their use in single and combination therapy for B-cell disorders are reviewed. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：211 / 222

页数：12

共 50 条

[1] BLOCKING B-CELLS (ANTI-CD20/ANTI-CD20)
Isenberg, David A.
[J]. RHEUMATOLOGY, 2015, 54 : 1 - 1
[2] Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targets
Maloney, DG
[J]. SEMINARS IN ONCOLOGY, 2005, 32 (01) : S19 - S26
[3] Anti-CD20 in lupus
Isenberg, DA
Leandro, MJ
Ehrenstein, MR
Edwards, JCW
Manson, J
Cambridge, G
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 27 - 28
[4] Anti-CD20 for rheumatoid arthritis
Edwards, JC
Leandro, MJ
Cambridge, G
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 25 - 25
[5] Combination anti-CD20 immunotherapy and pretargeted anti-CD20 radioimmunotherapy (PT-RAIT) of non-Hodgkin lymphoma (NHL) shows improved efficacy
Goldenberg, David M.
Karacay, Habibe
Chang, Chien-Hsing
Rossi, Edmund A.
McBride, William J.
Sharkey, Robert M.
[J]. JOURNAL OF NUCLEAR MEDICINE, 2009, 50
[6] Anti-CD20 in hematologic oncology
Milpied, Noel
[J]. PRESSE MEDICALE, 2009, 38 (05): : 788 - 798
[7] Can NK cells play a role in anti-CD20 immunotherapy for CLL patients?
Le Garff-Tavemier, Magali
De Romeuf, Christophe
Teillaud, Jean-Luc
Decocq, Julie
Dutertre, Charles-Antoine
Debre, Patrice
Merle-Beral, Helene
Vieillard, Vincent
[J]. BLOOD, 2007, 110 (11) : 913A - 913A
[8] Predictors of response and differential mechanisms of action for anti-CD20 radio-immunotherapy
Macklis, RM
Gokhale, A
Mayadev, J
Gupta, D
Pohlman, B
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S423 - S423
[9] Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV
Seto, Wai-Kay
Chan, Thomas Sau-Yan
Hwang, Yu-Yan
Mak, Lung-Yi
Wong, Danny Ka-Ho
Fung, James
Liu, Kevin Sze-Hang
Cheung, Ka-Shing
Lai, Ching-Lung
Kwong, Yok-Lam
Yuen, Man-Fung
[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (07) : 1410 - 1412
[10] HDAC6 Inhibition Increases Translation of CD20 mRNA and Potentiates the Efficacy of Anti-CD20 Immunotherapy
Bobrowicz, Malgorzata
Stachura, Joanna
Dwojak, Michal
Domagala, Antoni
Pyrzynska, Beata
Berthel, Elise
Venezia, Nicole Dalla
Siernicka, Marta
Firczuk, Malgorzata
Winiarska, Magdalena
[J]. BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →